



## FREQUENTLY ASKED QUESTIONS

---

**Q: In the Request to Participate Document, there is 3 Lots described for different goals and use cases. If our innovative technology can offer solution for multiple Lots simultaneously, can we combine the proposal and also the budget?**

**A:** At this stage, suppliers can express their interest to participate in multiple Lots. Following the completion of the Dialogue session(s) and the eventual invitation to submit their final binding offer, suppliers can submit technical and financial offer for one or more Lots. Should there be a possibility to combine proposals and budget, this will be considered by the Buyers' Group and will be included as a specific clause in the Call for Tenders.

**Q: The platform's home page is in Greek, and I cannot find how to access the English version of the platform.**

**A:** You need to Follow the instructions to get the credentials (document with guidance uploaded in our project website). Having received the credentials, you can have access to the platform (in English), to the invitation (no 179539) and the respective documentation.

**Q: Could you please confirm whether for a Power of Attorney an Apostille should be affixed?**

**A:** No, an Apostille is not requested.

**Q: Which regulation is applied regarding the access of third-country economic operators?**

**A:** In our current Notice, as launched after the 30.06.2022, the REGULATION (EU) 2022/1031 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL, of 23 June 2022 on the access of third-country economic operators, goods and services to the Union's public procurement and concession markets and procedures supporting negotiations on access of Union economic operators, goods and services to the public procurement and concession markets of third countries (International Procurement Instrument – IPI), applies.

**Q: Which legal entities are eligible for participation?**

**A:** Based on the DrugDetect Tender, a legal entity established or deemed to be established in EU Member, under the sense of Article 3 (b)(i) of the EU IPI Regulation is eligible for participation DrugDetect PPI.

**Q: Can you confirm that the intention is to use true 3-D CT (e.g. generated by rotating gantry technology) or will Multiview X-Ray (e.g. multiple 2-D images) meet the requirement in for this Lot?**

**A:** We can confirm that the intention is to use 3D CT but that Multiview X-ray technology is considered as a valid, suitable alternative. The exact requirements for lot 2 will be presented to a selected number of participants at a later stage.

**Q: DJI and DGEPI will award the contracts in Lot 2 under the condition that X-ray and CT technology is integrated with IMS” Would an MS based technology be considered for Lot 2 instead of IMS?**

**A:** The idea is that the integration of X-ray/CT-technology with a second technique like IMS will help in identifying\* whether a drug is present. In our opinion the second technique doesn't need to be IMS specific. Any other MS-based technique that is capable of identifying drugs will fulfill.

\* *Identification* refers to the analysis and conclusion regarding to the type of a substance, characterizing it as a drug.

**Q: Can you define "minimal operator interaction" as stated in DrugDetect PPI RtP Part I.5 Lot 1-3 Descriptions? Does this mean a corrections officer should not be expected to swab suspected drugs, packages, or persons as is common with many IMS/trace technologies?**

**A:** With “minimal operator interaction” it is meant that the required number of human interactions to be able to do a measurement/operate the equipment should be as limited as possible. The amount of time it takes for a person to do a measurement should be limited as well. Swabbing suspected objects therefor can be part of the measurement procedure. Ideally, the measurement process is fully automated. Proposals will receive a higher score when they propose a higher level of automation of the measurement process.

**Q: Would subcontracting training on devices fall under this category and require completion of the ESPD by each subcontractor or is it only in reference to development of the overall hardware solution?**

**A:** There is no distinction foreseen. All subcontractors should submit the ESPD.

**Q: Can you confirm that for Phase 1 (submission FEB 10) the only required documents to be submitted are the documents referenced in the “DrugDetect PPI RtP PartIII.1.1” (i.e. no pricing or technical specifications required for initial submission?) -ESPD -CVs for technical and project managers -Reference case for similar projects within 5 years**

**A:** Yes, we confirm. At this stage, the ESPD, CVs and reference case are requested.

**Q: When is the deadline for the submission?**

**A:** The due date for submitting applications is 10/02/23.

**Q: How can I get more support in the platform?**

**A:** In order to get support on NEPPS, we strongly recommend using the following email address to submit your request: [support@eprocurement.gov.gr](mailto:support@eprocurement.gov.gr)